Standardized Lion's Mane Mushroom Extract Improves Cognitive Scores in Older Adults

As research into healthy aging and neurogenesis has expanded, Lion's Mane mushroom (Hericium erinaceus) has transitioned from a traditional culinary delicacy to one of the most widely used structural nootropics in the world. While pre-clinical cell culture assays demonstrated that its active diterpenes could stimulate the synthesis of Nerve Growth Factor (NGF) in astrocytes, proving its real-world efficacy in humans required rigorous clinical testing.

To address this, researchers designed a double-blind, randomized, placebo-controlled trial evaluating oral Lion's Mane supplementation in older adults showing early signs of cognitive decline.

This research explainer provides a detailed breakdown of the trial design, cognitive scoring instruments, clinical outcomes, and limitations of this study.

---

1. Study Design & Participant Criteria

The study was designed as a randomized, double-blind, placebo-controlled clinical trial conducted over a 16-week intervention period, followed by a 4-week washout (observation) phase (20 weeks total).

Participant Profiles

The trial enrolled thirty Japanese adults (aged 50 to 80) who met the following inclusion criteria:

• Diagnosed with mild cognitive impairment (MCI) based on standardized screening tools.
• Showing mild, age-related cognitive decline but capable of independent daily living tasks.
• Having normal baseline blood panels and liver/kidney function.
• No history of severe psychiatric illness, stroke, or advanced dementia.
• No concurrent use of prescription acetylcholinesterase inhibitors.

Evaluating individuals with mild cognitive impairment is crucial. MCI represents the transition window between normal age-related memory slip and clinical dementia. Intervening in this window when neurogenesis pathways are still active provides the best opportunity to observe structural, growth-factor-driven adaptations.

The Intervention

Participants were randomly divided into two groups:

1. The Active Group (15 subjects): Received three 1,000 mg tablets containing dry Lion's Mane powder daily (3,000 mg total daily) taken with meals for 16 weeks.
2. The Control Group (15 subjects): Received an identical placebo tablet.

---

2. Measurement Methodology

To measure cognitive changes, researchers combined longitudinal testing with safety monitoring:

Cognitive Function Scale (Based on the Hasegawa Dementia Scale)

Cognitive performance was evaluated at baseline (Week 0), and at Weeks 8, 12, and 16 of the active phase, and at Week 20 (after the 4-week washout). The testing battery evaluated:

• Orientation (time and place recognition).
• Immediate and delayed recall (word retention and memory association).
• Visual attention and psychomotor speed.
• Calculations and working memory.

Safety and Tolerability Assays

At Weeks 0, 8, 16, and 20, researchers performed standard clinical chemistry blood draws, urinalyses, and physical examinations to monitor liver enzymes (AST, ALT), kidney markers, and blood pressure.

---

3. Primary Outcomes & Findings

The study demonstrated statistically significant improvements in cognitive performance for the active Lion's Mane group during the 16-week supplementation window compared to the placebo group.

       Cognitive Performance Scores (Day 0 to Week 20)
┌──────────────────────────────────────────────┐
│Active Group: Significant progressive increase │
│              (Drops back during washout)     │
├──────────────────────────────────────────────┤
│Placebo Group: Unchanged / Flat baseline      │
└──────────────────────────────────────────────┘

Key Statistical Results

Progressive Cognitive Improvement:

• The active group showed a statistically significant, progressive increase in cognitive scores at Weeks 8, 12, and 16 compared to baseline.
• The placebo group showed no significant change.
• The researchers noted that the difference in scores between the two groups grew wider over the duration of the trial, suggesting that the benefits accumulate over time as neuroplasticity pathways develop.

The Washout Decline:

• At Week 20 — four weeks after participants stopped taking the tablets — cognitive scores in the active group declined significantly, returning close to their baseline levels.
• This is a critical observation, confirming that Lion's Mane does not permanently cure cognitive decline. Its structural benefits (neurogenesis, synaptic repair) require continuous, daily support to be maintained.

---

4. Understanding the Molecular Mechanism

The cognitive improvements observed in this human trial are supported by the molecular biochemistry of Hericium erinaceus:

Astrocytic NGF Synthesis

As explained in the Lion's Mane profile, the active erinacines (from the mycelium) and hericenones (from the fruiting body) cross the blood-brain barrier:

• They bind to receptors on astrocytes, prompting them to synthesize and secrete Nerve Growth Factor (NGF).
• Elevated NGF levels support the survival of sensory neurons and encourage synaptogenesis (the growth of new connections) and adult neurogenesis in the hippocampus.
• When the supplement is stopped, NGF levels decline, and the newly formed but uninsulated synapses are pruned away over time, explaining the post-trial score drop.

Myelin Sheath Maintenance

NGF supports the activity of oligodendrocytes — the cells responsible for manufacturing myelin. Myelin wraps around neuronal axons, acting as electrical insulation to prevent signal decay and accelerate signal travel speed. Supported myelination is reflected in the cognitive processing speed improvements observed during testing.

---

5. Safety and Tolerability Parameters

• Excellent Hepatic and Renal Safety: Blood biochemistry markers remained stable throughout the study. AST, ALT, serum creatinine, and BUN levels showed no adverse changes.
• No Side Effects Reported: No participants withdrew from the study due to supplement-related adverse effects, and zero instances of digestive distress, skin irritation, or sleep changes were reported.

---

6. Trial Limitations and Future Research Needs

• Small Cohort Size: Thirty subjects is a small study. Larger, multi-center trials with 100+ subjects are needed to confirm these findings in broader populations.
• Use of Raw Powder vs. Concentrated Extract: The study used 3,000 mg of raw dry powder. Concentrated extracts standardized for beta-glucans and active diterpenes may yield equivalent or superior results at lower daily doses (500–1,000 mg).
• Indirect NGF Measurement: Because measuring brain tissue NGF requires spinal taps or biopsies, researchers could not directly measure brain NGF levels in the subjects. Future studies should monitor serum NGF or BDNF as systemic biomarkers of neural growth activity.

This guide is for educational purposes only. Readers should consult qualified healthcare professionals before starting, altering, or combining any supplement routine.